No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 28 of the 40 quarters in the window, leaving 12 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 36
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:04:51.665Z. Latest historical point 2024-03-15. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T22:04:51.665Z. Latest historical point 2022-08-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T22:04:51.665Z. Latest historical point 2022-08-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:04:51.665Z. Latest historical point 2022-08-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:04:51.665Z. Latest historical point 2022-08-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for XBiotech Inc. (XBIT) stock was $2.16 as of Oct 6, 2026, 4:00 PM EDT, down 0.92% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -17.4% · 3-year avg -18.4%/yr · 5-year avg -29.4%/yr
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies.
Biotechnology · Austin, TX
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$0.00
vs Estimate
$0.06
Revenue
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1XBIT | $65.85M | $2.16 | -0.92% | -17.35% | -29.36% | -15.76% | N/A |
| 2CING | $65.86M | $4.89 | +2.95% | +13.57% | N/A | N/A | vs XBIT |
| 3GOSS | $65.87M | $10.78 | +1.22% | -94.75% | -59.51% | N/A | vs XBIT |
| 4IBIO | $67.52M | $1.05 | -6.25% | +30.14% | -70.43% | -54.11% | vs XBIT |
| 5ALPS | $64.18M | $0.39 | -3.58% | N/A | N/A | N/A | vs XBIT |
| 6PLRX | $63.78M | $1.03 | +0.00% | -32.11% | -43.17% | N/A | vs XBIT |
forward FY estimate
N/A
vs Estimate
$7.00M
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$2.16
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.02 | $0.02 | $0.02 | 1 |
| Quarter ending Dec 2026 | $0.04 | $0.04 | $0.04 | 1 |
| Quarter ending Mar 2027 | $0.03 | $0.03 | $0.03 | 1 |
| Quarter ending Jun 2027 | $0.03 | $0.03 | $0.03 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $7.00M | $7.00M | $7.00M | 1 |
| Quarter ending Dec 2026 | $7.00M | $7.00M | $7.00M | 1 |
| Quarter ending Mar 2027 | $7.00M | $7.00M | $7.00M | 1 |
| Quarter ending Jun 2027 | $7.00M | $7.00M | $7.00M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
